Leukemia FAQ
Leukemia FAQ
The questions on this page come after the medical ones have been answered — what treatment will cost, how long the patient will be away from home, which drugs can actually be given here, and what happens on return. They are answered separately on purpose, because planning around them is what makes an intensive regimen easier to complete and a long one easier to sustain.
What treatment costs
Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on which parts of the pathway you need:
- Diagnosis and molecular testing — the marrow examination, flow cytometry, chromosome analysis and gene testing, which are comparatively inexpensive individually but are what the whole plan depends on.
- Chemotherapy phases — priced by the phase rather than the dose, so the total accumulates over induction, consolidation and, in acute lymphoblastic leukemia, maintenance over several years.
- Targeted drugs — an oral tyrosine kinase inhibitor taken continuously, or a targeted agent added to chemotherapy; across months or years these become a substantial part of the total.
- Cell therapy and transplant — the largest single components, because they require weeks of inpatient care, protective isolation, intensive support and prolonged follow-up.
- Supportive care — anti-infective prophylaxis, transfusions, growth factors and complication management, individually modest and collectively a real part of the bill during intensive treatment.
How long you will need to stay
The length of a stay is determined by the type of leukemia rather than by any general rule:
- Diagnosis and molecular testing — usually one to two weeks, since the marrow results and the molecular panel need time to be reported.
- Induction for acute myeloid leukemia — an inpatient stay of four to six weeks, because counts fall before they recover and supportive care is needed throughout.
- Consolidation — shorter admissions of a few days to a couple of weeks, with intervals between them.
- Acute lymphoblastic leukemia — an initial stay measured in weeks, followed by a programme delivered partly as an outpatient over two to three years.
- Chronic myeloid leukemia — no admission for routine treatment; monitoring is by blood tests, and most patients are seen as outpatients.
- Transplant — several weeks of inpatient care including the period of low counts, followed by outpatient monitoring before travel is considered.
Which medicines are available
Most medicines used in leukemia internationally are available here:
- Standard chemotherapy drugs — cytarabine, anthracyclines, vincristine, asparaginase and the others that make up the regimens, at the same doses used internationally.
- All-trans retinoic acid and arsenic trioxide — the two drugs used to treat acute promyelocytic leukemia, which must be available without delay.
- Tyrosine kinase inhibitors — several generations of them, including those active against the mutation that makes earlier drugs ineffective.
- Other targeted agents — FLT3 inhibitors, IDH inhibitors and the BCL2 inhibitor used with a hypomethylating agent.
- Bispecific antibodies and antibody-drug conjugates — including agents directed at CD19 and at CD22.
- Bruton tyrosine kinase inhibitors — used continuously in chronic lymphocytic leukemia.
- CAR T-cell therapy — engineered cells directed at CD19, for relapsed or refractory B-cell acute lymphoblastic leukemia.
Sending records and receiving a written opinion
The most useful thing to send is the original documents rather than a summary:
- The marrow aspirate and biopsy reports, in full, or better the slides themselves, which allow the diagnosis to be reviewed directly rather than repeated.
- The flow cytometry panel — the markers reported, since these define the lineage and provide the marker used later to measure residual disease.
- The chromosome and molecular results — the full report rather than the conclusion, because the risk group is assigned from the details.
- The treatment history — which regimen, which phases, the dates, any dose reductions, and the response at each assessment.
- Recent blood counts — with the film report, and previous counts for comparison where available.
Insurance and payment
Coverage varies more than for most conditions, because so much of the cost sits in drugs:
- Check whether the policy covers treatment outside your country of residence before assuming it does, and whether prior authorisation is required.
- Check the drug coverage specifically — targeted agents taken continuously are often treated differently from inpatient care, and cell therapy is frequently excluded or capped.
- Check the transplant cover, including donor search, the admission itself and the months of follow-up, since these are often bundled or limited.
- Ask whether direct billing is available for your insurer, since paying and reclaiming is a different financial exercise from direct settlement, and the sums involved in transplant are large.
- Request the documentation the insurer requires at the outset — a treatment plan, a cost estimate and clinical justification are usually needed, and they take time to assemble.
After treatment, and back home
Cross-border treatment makes written handover more important than in most conditions:
- A written summary of the treatment actually given — drug names, cumulative doses including any anthracycline, the phases completed, and the response at the end of each.
- A follow-up schedule with defined intervals — when counts and marrow assessments are due, and how the intervals lengthen over time.
- Prophylaxis that continues — anti-infective medication, and the vaccination schedule, since live vaccines are avoided for a period after treatment.
- Awareness of what to report — a new fever, unusual bruising or bleeding, or infections becoming more frequent, which may indicate that counts have fallen.
- Late effects to watch for — cardiac function after an anthracycline, endocrine and thyroid function after total body irradiation, and graft-versus-host disease after a transplant.
- A named contact, for questions between visits and for arranging a video review of results taken elsewhere.
Eating and daily life during treatment
No diet treats leukemia. What nutrition can do is support you through treatment:
- Food safety matters more than food choice. During and after intensive chemotherapy the immune system is suppressed, so avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood, and unwashed produce is a concrete protective measure.
- Adequate protein and calories to maintain weight, since weight loss during treatment is common and affects how the next phase is tolerated.
- Mouth care — mucositis is common with several regimens, and rinsing, gentle cleaning and treating pain early make it manageable rather than a reason to stop eating.
- Managing nausea and taste changes, which should be treated with adjusted anti-sickness medication rather than endured.
- Neutropenic precautions at home — avoiding crowded settings during the lowest point of the blood count, and reporting a fever immediately rather than monitoring it.
- Supplements — discussed with the team first, because some interact with treatment and some are marketed without evidence of benefit.